Sr Director, Federal Drug Pricing Policy

At Gilead, we’re creating a healthier world for all people. For more than 35 years, we’ve tackled diseases such as HIV, viral hepatitis, COVID-19 and cancer – working relentlessly to develop therapies that help improve lives and to ensure access to these therapies across the globe. We continue to fight against the world’s biggest health challenges, and our mission requires collaboration, determination and a relentless drive to make a difference.

Every member of Gilead’s team plays a critical role in the discovery and development of life-changing scientific innovations. Our employees are our greatest asset as we work to achieve our bold ambitions, and we’re looking for the next wave of passionate and ambitious people ready to make a direct impact.

We believe every employee deserves a great leader. People Leaders are the cornerstone to the employee experience at Gilead and Kite. As a people leader now or in the future, you are the key driver in evolving our culture and creating an environment where every employee feels included, developed and empowered to fulfil their aspirations. Join Gilead and help create possible, together.

Job Description

The Senior Director, Federal Drug Pricing Policy drives strategic analysis and the development of policy and advocacy materials to address federal drug pricing reforms, including the Inflation Reduction Act (IRA) and Most Favored Nation proposals. This role also will partner on initiatives to articulate and demonstrate the value of medicines, including preparation for potential US value assessments and informing evidence generation strategies for in-line and late-stage pipeline products.

Job Description

The Senior Director, Federal Drug Pricing Policy leads strategic analysis and the development of policy and advocacy materials to address federal drug pricing reforms, including the Inflation Reduction Act (IRA) and Most Favored Nation proposals. This role also will partner on initiatives to articulate and demonstrate the value of medicines, including preparation for potential US value assessments and informing evidence generation strategies for in-line and late-stage pipeline products.

This position provides leadership in US pricing policy and analytics to mitigate policy-related risks, protect patient access, and support the sustainable value of current and future medicines. With accountability for strategic positioning in response to US drug pricing reform, the role has broad impact across the US portfolio and pipeline and provides recommendations to senior leadership to inform decision-making on U.S. pricing policy strategy.